CC BY-NC-ND 4.0 · Endosc Int Open 2021; 09(08): E1178-E1185
DOI: 10.1055/a-1479-2199
Original article

Long-term outcome after EUS-guided radiofrequency ablation: Prospective results in pancreatic neuroendocrine tumors and pancreatic cystic neoplasms

Marc Barthet
1  Hopital Nord – Gastroenterology, Marseille, France
,
Marc Giovannini
2  Paoli Calmettes Institute – Endoscopic Unit, Marseille, France
,
Mohamed Gasmi
1  Hopital Nord – Gastroenterology, Marseille, France
,
Nathalie Lesavre
1  Hopital Nord – Gastroenterology, Marseille, France
,
Christian Boustière
3  Hôpital St-Joseph – Gastroenterology, Marseille, France
,
Bertrand Napoleon
4  Centre Chirurgical Lyon Mermoz – Endoscopy Unit, Lyon, France
,
Arthur LaQuiere
3  Hôpital St-Joseph – Gastroenterology, Marseille, France
,
Stephane Koch
5  CHRU Minjoz, Besancon, French Polynesia
,
Geoffroy Vanbiervliet
6  Hôpital de L’Archet 2 – Pôle digestif, Nice France
,
Jean-Michel Gonzalez
1  Hopital Nord – Gastroenterology, Marseille, France
› Author Affiliations

Abstract

Background and study aims Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) for pancreatic neuroendocrine tumors (NETs) and intraductal pancreatic mucinous neoplasia (IPMN) with worrisome features or high-risk stigmata (WF/HRS) has been evaluated in few series with short-term outcomes. This studyʼs primary endpoint was to assess the long-term efficacy of EUS-RFA in patients with NETs or pancreatic cystic neoplasms (PCNs) over at least 3 years.

Patients and methods Twelve patients had 14 NETs with a mean 13.4-mm size (10–20) and 17 patients had a cystic tumor (16 IPMN, 1 MCA) with a 29.1-mm mean size (9–60 were included. They were treated with EUS-guided RFA, evaluated prospectively at 1 year, and followed annually for at least 3 years.

Results The mean duration of follow-up was 42.9 months (36–53). Four patients died during follow-up (17–42 months) from unrelated diseases.

At 1-year follow-up, and 85.7 % complete disappearance was seen in 12 patients with 14 NETs. At the end of follow-up (45.6 months), complete disappearance of tumors was seen in 85.7 % of cases. One case of late liver metastasis occurred in a patient with initial failure of EUS-RFA. At 1-year follow-up, a significant response was seen in 70.5 % of 15 patients with PCNs. At the end of the follow-up, there was a significant response in 66.6 % with no mural nodules. Two cases of distant pancreatic adenocarcinoma unrelated to IPMN occurred.

Conclusions EUS-RFA results for pancreatic NETs or PCNs appear to be stable during 42 months of follow-up.



Publication History

Received: 26 August 2020

Accepted: 29 October 2020

Publication Date:
16 July 2021 (online)

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany